These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 12181083)

  • 1. [Clinical efficacy and safety of huperzine Alpha in treatment of mild to moderate Alzheimer disease, a placebo-controlled, double-blind, randomized trial].
    Zhang Z; Wang X; Chen Q; Shu L; Wang J; Shan G
    Zhonghua Yi Xue Za Zhi; 2002 Jul; 82(14):941-4. PubMed ID: 12181083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial.
    Freund-Levi Y; Eriksdotter-Jönhagen M; Cederholm T; Basun H; Faxén-Irving G; Garlind A; Vedin I; Vessby B; Wahlund LO; Palmblad J
    Arch Neurol; 2006 Oct; 63(10):1402-8. PubMed ID: 17030655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Donepezil preserves cognition and global function in patients with severe Alzheimer disease.
    Black SE; Doody R; Li H; McRae T; Jambor KM; Xu Y; Sun Y; Perdomo CA; Richardson S
    Neurology; 2007 Jul; 69(5):459-69. PubMed ID: 17664405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclandelate in the treatment of patients with mild to moderate primary degenerative dementia of the Alzheimer type or vascular dementia: experience from a placebo controlled multi-center study.
    Weyer G; Eul A; Milde K; Wierich W; Herrmann WM
    Pharmacopsychiatry; 2000 May; 33(3):89-97. PubMed ID: 10855459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicentre, randomized, double-blind, placebo-controlled study to evaluate the efficacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate Alzheimer's disease: the MALT study.
    Dubois B; McKeith I; Orgogozo JM; Collins O; Meulien D
    Int J Geriatr Psychiatry; 1999 Nov; 14(11):973-82. PubMed ID: 10556869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer's disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion.
    Alvarez XA; Mouzo R; Pichel V; Pérez P; Laredo M; Fernández-Novoa L; Corzo L; Zas R; Alcaraz M; Secades JJ; Lozano R; Cacabelos R
    Methods Find Exp Clin Pharmacol; 1999 Nov; 21(9):633-44. PubMed ID: 10669911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial.
    Doody RS; Ferris SH; Salloway S; Sun Y; Goldman R; Watkins WE; Xu Y; Murthy AK
    Neurology; 2009 May; 72(18):1555-61. PubMed ID: 19176895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Galantamine treatment of vascular dementia: a randomized trial.
    Auchus AP; Brashear HR; Salloway S; Korczyn AD; De Deyn PP; Gassmann-Mayer C;
    Neurology; 2007 Jul; 69(5):448-58. PubMed ID: 17664404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atomoxetine augmentation of cholinesterase inhibitor therapy in patients with Alzheimer disease: 6-month, randomized, double-blind, placebo-controlled, parallel-trial study.
    Mohs RC; Shiovitz TM; Tariot PN; Porsteinsson AP; Baker KD; Feldman PD
    Am J Geriatr Psychiatry; 2009 Sep; 17(9):752-9. PubMed ID: 19700948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Huperzine-A in capsules and tablets for treating patients with Alzheimer disease.
    Xu SS; Cai ZY; Qu ZW; Yang RM; Cai YL; Wang GQ; Su XQ; Zhong XS; Cheng RY; Xu WA; Li JX; Feng B
    Zhongguo Yao Li Xue Bao; 1999 Jun; 20(6):486-90. PubMed ID: 10678137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: a preliminary randomized double-blind placebo-controlled study.
    Chiu CC; Su KP; Cheng TC; Liu HC; Chang CJ; Dewey ME; Stewart R; Huang SY
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1538-44. PubMed ID: 18573585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of tablet huperzine-A on memory, cognition, and behavior in Alzheimer's disease.
    Xu SS; Gao ZX; Weng Z; Du ZM; Xu WA; Yang JS; Zhang ML; Tong ZH; Fang YS; Chai XS
    Zhongguo Yao Li Xue Bao; 1995 Sep; 16(5):391-5. PubMed ID: 8701750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease.
    Burns A; Spiegel R; Quarg P
    Int J Geriatr Psychiatry; 2004 Mar; 19(3):243-9. PubMed ID: 15027039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AMPA potentiator treatment of cognitive deficits in Alzheimer disease.
    Chappell AS; Gonzales C; Williams J; Witte MM; Mohs RC; Sperling R
    Neurology; 2007 Mar; 68(13):1008-12. PubMed ID: 17389305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between pharmacodynamic activity and cognitive effects of eptastigmine in patients with Alzheimer's disease. Eptastigmine Study Group.
    Canal N; Imbimbo BP
    Clin Pharmacol Ther; 1996 Aug; 60(2):218-28. PubMed ID: 8823240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Huperzine A for Alzheimer's disease.
    Li J; Wu HM; Zhou RL; Liu GJ; Dong BR
    Cochrane Database Syst Rev; 2008 Apr; (2):CD005592. PubMed ID: 18425924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of galantamine in patients with mild Alzheimer's disease.
    Orgogozo JM; Small GW; Hammond G; Van Baelen B; Schwalen S
    Curr Med Res Opin; 2004 Nov; 20(11):1815-20. PubMed ID: 15537482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Double-blind, randomized, placebo-controlled pilot study with anapsos in senile dementia: effects on cognition, brain bioelectrical activity and cerebral hemodynamics.
    Alvarez XA; Pichel V; Pérez P; Laredo M; Corzo D; Zas R; Fernández-Novoa L; Sempere JM; Díaz J; Cacabelos R
    Methods Find Exp Clin Pharmacol; 2000 Sep; 22(7):585-94. PubMed ID: 11196347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Galantamine treatment in Alzheimer's disease with cerebrovascular disease: responder analyses from a randomized, controlled trial (GAL-INT-6).
    Erkinjuntti T; Gauthier S; Bullock R; Kurz A; Hammond G; Schwalen S; Zhu Y; Brashear R
    J Psychopharmacol; 2008 Sep; 22(7):761-8. PubMed ID: 18308781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.